DK3011029T3 - Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering - Google Patents
Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering Download PDFInfo
- Publication number
- DK3011029T3 DK3011029T3 DK14734708.2T DK14734708T DK3011029T3 DK 3011029 T3 DK3011029 T3 DK 3011029T3 DK 14734708 T DK14734708 T DK 14734708T DK 3011029 T3 DK3011029 T3 DK 3011029T3
- Authority
- DK
- Denmark
- Prior art keywords
- optimization
- administration
- procedures
- compositions
- modification
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000005457 optimization Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361836123P | 2013-06-17 | 2013-06-17 | |
US201361847537P | 2013-07-17 | 2013-07-17 | |
US201361862468P | 2013-08-05 | 2013-08-05 | |
US201361862355P | 2013-08-05 | 2013-08-05 | |
US201361871301P | 2013-08-28 | 2013-08-28 | |
US201361915407P | 2013-12-12 | 2013-12-12 | |
US201461979942P | 2014-04-15 | 2014-04-15 | |
PCT/US2014/041800 WO2014204724A1 (en) | 2013-06-17 | 2014-06-10 | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3011029T3 true DK3011029T3 (da) | 2020-03-16 |
Family
ID=51059658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14734708.2T DK3011029T3 (da) | 2013-06-17 | 2014-06-10 | Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering |
Country Status (11)
Country | Link |
---|---|
US (2) | US11008588B2 (da) |
EP (2) | EP3674411A1 (da) |
JP (2) | JP6625971B2 (da) |
KR (1) | KR20160044457A (da) |
CN (1) | CN106062197A (da) |
AU (1) | AU2014281026B2 (da) |
CA (1) | CA2915834A1 (da) |
DK (1) | DK3011029T3 (da) |
ES (1) | ES2777217T3 (da) |
HK (1) | HK1223646A1 (da) |
WO (1) | WO2014204724A1 (da) |
Families Citing this family (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
RS64622B1 (sr) | 2012-05-25 | 2023-10-31 | Univ California | Metode i sastavi za modifikaciju ciljane dnk upravljenu pomoću rnk i za modulaciju transkripcije upravljanu rnk |
ES2757623T3 (es) * | 2012-07-25 | 2020-04-29 | Broad Inst Inc | Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas |
JP6517143B2 (ja) | 2012-10-23 | 2019-05-22 | ツールゲン インコーポレイテッド | 標的dnaに特異的なガイドrnaおよびcasタンパク質コード核酸またはcasタンパク質を含む、標的dnaを切断するための組成物、ならびにその使用 |
EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
EP4286402A3 (en) | 2012-12-12 | 2024-02-14 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
US10119133B2 (en) | 2013-03-15 | 2018-11-06 | The General Hospital Corporation | Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing |
US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
RS58255B1 (sr) | 2013-04-16 | 2019-03-29 | Regeneron Pharma | Ciljana modifikacija genoma pacova |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
SG10201710487VA (en) * | 2013-06-17 | 2018-01-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components |
KR20160044457A (ko) | 2013-06-17 | 2016-04-25 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 탠덤 안내 시스템, 방법 및 조성물의 전달, 조작 및 최적화 |
AU2014281027A1 (en) | 2013-06-17 | 2016-01-28 | Massachusetts Institute Of Technology | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
RU2716420C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
EP3418379B1 (en) | 2013-09-18 | 2020-12-09 | Kymab Limited | Methods, cells & organisms |
WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
US10584358B2 (en) | 2013-10-30 | 2020-03-10 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
KR102523466B1 (ko) | 2013-11-07 | 2023-04-20 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
AU2014362248A1 (en) | 2013-12-12 | 2016-06-16 | Massachusetts Institute Of Technology | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
SG10201804976YA (en) * | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing |
JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物 |
US10787654B2 (en) | 2014-01-24 | 2020-09-29 | North Carolina State University | Methods and compositions for sequence guiding Cas9 targeting |
AU2015222944A1 (en) | 2014-02-27 | 2016-09-08 | Massachusetts Institute Of Technology | T cell balance gene expression, compositions of matters and methods of use thereof |
CN106460003A (zh) | 2014-04-08 | 2017-02-22 | 北卡罗来纳州立大学 | 用于使用crispr相关基因rna引导阻遏转录的方法和组合物 |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
EP3180426B1 (en) | 2014-08-17 | 2019-12-25 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
EP3186375A4 (en) | 2014-08-28 | 2019-03-13 | North Carolina State University | NEW CAS9 PROTEINS AND GUIDING ELEMENTS FOR DNA TARGETING AND THE GENOME EDITION |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
ES2741387T3 (es) | 2014-10-15 | 2020-02-10 | Regeneron Pharma | Métodos y composiciones para generar o mantener células pluripotentes |
US20170247762A1 (en) | 2014-10-27 | 2017-08-31 | The Board Institute Inc. | Compositions, methods and use of synthetic lethal screening |
US10725041B2 (en) * | 2014-11-04 | 2020-07-28 | Versiti Blood Research Institute Foundation, Inc. | Method to bioengineer designer platelets using gene editing and stem cell methodologies |
CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
PT3221457T (pt) | 2014-11-21 | 2019-06-27 | Regeneron Pharma | Métodos e composições para modificação genética visada através da utilização de arn guia emparelhados |
WO2016086197A1 (en) | 2014-11-25 | 2016-06-02 | The Brigham And Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
WO2016089433A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
EP3230452A1 (en) | 2014-12-12 | 2017-10-18 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
AU2015369725A1 (en) | 2014-12-24 | 2017-06-29 | Massachusetts Institute Of Technology | CRISPR having or associated with destabilization domains |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
AU2015373893B2 (en) * | 2014-12-31 | 2021-07-29 | Synthetic Genomics, Inc. | Compositions and methods for high efficiency in vivo genome editing |
FI3250691T3 (fi) | 2015-01-28 | 2023-08-24 | Caribou Biosciences Inc | Crispr hybridi dna/rna polynukleotidit ja käyttömenetelmät |
WO2016130697A1 (en) * | 2015-02-11 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Methods and kits for generating vectors that co-express multiple target molecules |
EP3262193A2 (en) | 2015-02-26 | 2018-01-03 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
KR20230156800A (ko) * | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
GB201506509D0 (en) | 2015-04-16 | 2015-06-03 | Univ Wageningen | Nuclease-mediated genome editing |
WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
AU2016261358B2 (en) | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
AU2016265255B2 (en) * | 2015-05-16 | 2022-03-17 | Genzyme Corporation | Gene editing of deep intronic mutations |
JP2018516563A (ja) | 2015-05-29 | 2018-06-28 | ノース カロライナ ステート ユニバーシティNorth Carolina State University | Crispr核酸を用いて、細菌、古細菌、藻類、および、酵母をスクリーニングする方法 |
CN116334142A (zh) | 2015-06-09 | 2023-06-27 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
CA2983874C (en) | 2015-06-15 | 2022-06-21 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
US10648020B2 (en) | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
KR102575342B1 (ko) | 2015-06-18 | 2023-09-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적외 효과를 감소시키는 crispr 효소 돌연변이 |
FI3430134T3 (fi) | 2015-06-18 | 2023-01-13 | Uusia CRISPR-entsyymejä ja järjestelmiä | |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
EP3436575A1 (en) * | 2015-06-18 | 2019-02-06 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
US11414657B2 (en) | 2015-06-29 | 2022-08-16 | Ionis Pharmaceuticals, Inc. | Modified CRISPR RNA and modified single CRISPR RNA and uses thereof |
IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
US20180230450A1 (en) * | 2015-08-03 | 2018-08-16 | President And Fellows Of Harvard College | Cas9 Genome Editing and Transcriptional Regulation |
EP3337908A4 (en) | 2015-08-18 | 2019-01-23 | The Broad Institute, Inc. | METHOD AND COMPOSITIONS FOR CHANGING THE FUNCTION AND STRUCTURE OF CHROMATIN GRINDING AND / OR DOMAINS |
US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
CA3002647A1 (en) * | 2015-09-21 | 2017-03-30 | Arcturus Therapeutics, Inc. | Allele selective gene editing and uses thereof |
CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
EP3356533A1 (en) | 2015-09-28 | 2018-08-08 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017070605A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
US11492670B2 (en) | 2015-10-27 | 2022-11-08 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
WO2017075294A1 (en) | 2015-10-28 | 2017-05-04 | The Board Institute Inc. | Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction |
US11092607B2 (en) | 2015-10-28 | 2021-08-17 | The Board Institute, Inc. | Multiplex analysis of single cell constituents |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
WO2017112620A1 (en) | 2015-12-22 | 2017-06-29 | North Carolina State University | Methods and compositions for delivery of crispr based antimicrobials |
ES2944597T3 (es) | 2015-12-30 | 2023-06-22 | Novartis Ag | Terapias con células efectoras inmunitarias de eficacia mejorada |
EP3408396A4 (en) * | 2016-01-26 | 2019-10-09 | Cedars-Sinai Medical Center | IN VIVO DOUBLE RECOMBINASE MEDIATION (DRMCE) CASSETTE EXCHANGE SYSTEMS AND METHODS AND MODELS OF ASSOCIATED DISEASES |
EP3420102B1 (en) | 2016-02-22 | 2024-04-03 | Massachusetts Institute of Technology | Methods for identifying and modulating immune phenotypes |
US11427861B2 (en) | 2016-03-17 | 2022-08-30 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
WO2017189308A1 (en) * | 2016-04-19 | 2017-11-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
AU2017253107B2 (en) | 2016-04-19 | 2023-07-20 | Massachusetts Institute Of Technology | CPF1 complexes with reduced indel activity |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
CA3028158A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute, Inc. | Type vi crispr orthologs and systems |
JP7033583B2 (ja) | 2016-07-13 | 2022-03-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | ゲノム編集効率を高めるための方法、組成物及びキット |
US11608570B2 (en) * | 2016-07-29 | 2023-03-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Targeted in situ protein diversification by site directed DNA cleavage and repair |
IL264565B1 (en) | 2016-08-03 | 2024-03-01 | Harvard College | Adenosine nuclear base editors and their uses |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
EP3500671A4 (en) | 2016-08-17 | 2020-07-29 | The Broad Institute, Inc. | NEW CRISPR ENZYMS AND SYSTEMS |
US20210166783A1 (en) | 2016-08-17 | 2021-06-03 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
US20190185850A1 (en) * | 2016-08-20 | 2019-06-20 | Avellino Lab Usa, Inc. | Single guide rna/crispr/cas9 systems, and methods of use thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2017216392A1 (en) * | 2016-09-23 | 2017-12-21 | Dsm Ip Assets B.V. | A guide-rna expression system for a host cell |
US20190225974A1 (en) | 2016-09-23 | 2019-07-25 | BASF Agricultural Solutions Seed US LLC | Targeted genome optimization in plants |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
JP2019530464A (ja) | 2016-10-14 | 2019-10-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのaav送達 |
GB2605883B (en) | 2016-10-18 | 2023-03-15 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
BR112019009725A2 (pt) * | 2016-11-14 | 2019-11-19 | Toolgen Incorporated | sistema de controle de função de sc artificialmente manipulado |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
WO2018129486A2 (en) * | 2017-01-06 | 2018-07-12 | President And Fellows Of Harvard College | Composition and methods for enhanced knock-in reporter gene expression |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
CA3049989A1 (en) * | 2017-02-10 | 2018-08-16 | Zymergen Inc. | A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts |
GB201702847D0 (en) * | 2017-02-22 | 2017-04-05 | Cancer Res Tech Ltd | Cell labelling, tracking and retrieval |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
EP3596207B1 (en) | 2017-03-15 | 2023-12-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
WO2018170515A1 (en) | 2017-03-17 | 2018-09-20 | The Broad Institute, Inc. | Methods for identifying and modulating co-occurant cellular phenotypes |
WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
CN110914433A (zh) * | 2017-03-24 | 2020-03-24 | 库尔维科公司 | 编码crispr相关蛋白质的核酸及其用途 |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
WO2018191520A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
JP2020516285A (ja) | 2017-04-12 | 2020-06-11 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新規vi型crisprオルソログ及び系 |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
EP3612629A1 (en) | 2017-04-18 | 2020-02-26 | The Broad Institute, Inc. | Compositions for detecting secretion and methods of use |
US20200384115A1 (en) | 2017-04-21 | 2020-12-10 | The Broad Institute , Inc. | Targeted delivery to beta cells |
EP3615672A1 (en) | 2017-04-28 | 2020-03-04 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
WO2018204777A2 (en) | 2017-05-05 | 2018-11-08 | The Broad Institute, Inc. | Methods for identification and modification of lncrna associated with target genotypes and phenotypes |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CN111417727A (zh) | 2017-05-18 | 2020-07-14 | 博德研究所 | 用于靶向核酸编辑的系统、方法和组合物 |
WO2018217981A1 (en) | 2017-05-26 | 2018-11-29 | North Carolina State University | Altered guide rnas for modulating cas9 activity and methods of use |
EP3635113A4 (en) | 2017-06-05 | 2021-03-17 | Fred Hutchinson Cancer Research Center | GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND MANIPULATED NANOPARTICLES TO DELIVER TARGETED GENETIC THERAPIES |
US10428319B2 (en) | 2017-06-09 | 2019-10-01 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
CN111328290A (zh) | 2017-06-26 | 2020-06-23 | 博德研究所 | 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法 |
JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス,インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
US20200140896A1 (en) | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
IL271883B1 (en) * | 2017-07-12 | 2024-04-01 | Refuge Biotechnologies Inc | Systems and methods for conditional regulation of gene expression |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
JP7207665B2 (ja) | 2017-08-04 | 2023-01-18 | 北京大学 | メチル化により修飾されたdna塩基を特異的に認識するtale rvdおよびその使用 |
WO2019028686A1 (zh) | 2017-08-08 | 2019-02-14 | 北京大学 | 基因敲除方法 |
EP3672612A4 (en) | 2017-08-23 | 2021-09-29 | The General Hospital Corporation | MANIPULATED CRISPR-CAS9-NUCLEASES WITH CHANGED PAM SPECIFICITY |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
CN111511388A (zh) | 2017-09-21 | 2020-08-07 | 博德研究所 | 用于靶向核酸编辑的系统、方法和组合物 |
EP3692152A4 (en) | 2017-10-04 | 2021-12-01 | The Broad Institute, Inc. | PROCESSES AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND / OR DOMAINS |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
WO2019079362A1 (en) | 2017-10-16 | 2019-04-25 | Massachusetts Institute Of Technology | HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS |
MX2020004063A (es) | 2017-10-20 | 2020-10-05 | Hutchinson Fred Cancer Res | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. |
WO2019089803A1 (en) | 2017-10-31 | 2019-05-09 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
WO2019087113A1 (en) | 2017-11-01 | 2019-05-09 | Novartis Ag | Synthetic rnas and methods of use |
AU2018372763A1 (en) | 2017-11-21 | 2020-05-28 | Bayer Healthcare Llc | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa |
WO2019113506A1 (en) | 2017-12-07 | 2019-06-13 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
ES2940786T3 (es) | 2018-01-17 | 2023-05-11 | Vertex Pharma | Compuestos de quinoxalinona, composiciones, métodos y kits para aumentar la eficiencia de edición del genoma |
EP3740479A1 (en) | 2018-01-17 | 2020-11-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
CN111757876B (zh) | 2018-01-17 | 2024-03-22 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
CN108424934A (zh) * | 2018-04-16 | 2018-08-21 | 和元生物技术(上海)股份有限公司 | 一种慢病毒cag-cmv双启动子改造载体构建及应用 |
WO2019204585A1 (en) | 2018-04-19 | 2019-10-24 | Massachusetts Institute Of Technology | Single-stranded break detection in double-stranded dna |
PL3560330T3 (pl) | 2018-04-24 | 2022-09-19 | KWS SAAT SE & Co. KGaA | Rośliny o ulepszonej strawności i haplotypach markerowych |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019210268A2 (en) | 2018-04-27 | 2019-10-31 | The Broad Institute, Inc. | Sequencing-based proteomics |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
EP3578658A1 (en) * | 2018-06-08 | 2019-12-11 | Johann Wolfgang Goethe-Universität Frankfurt | Method for generating a gene editing vector with fixed guide rna pairs |
CN108846258B (zh) * | 2018-06-08 | 2021-05-18 | 中国人民解放军军事科学院军事医学研究院 | 一种自动检测分节段rna病毒重配的方法 |
WO2019237399A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | CRISPR-Cas9特异性敲除人C2orf40基因的方法及其特异的sgRNA |
SG11202012786RA (en) | 2018-06-26 | 2021-01-28 | Massachusetts Inst Technology | Crispr effector system based amplification methods, systems, and diagnostics |
BR112020025319A2 (pt) | 2018-06-26 | 2021-03-09 | The Broad Institute Inc. | Composições, sistemas e métodos de amplificação baseada em crispr/cas e transposase |
KR20210053898A (ko) | 2018-07-31 | 2021-05-12 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규 crispr 효소 및 시스템 |
CN113286884A (zh) | 2018-08-07 | 2021-08-20 | 博德研究所 | 新型cas12b酶和系统 |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
US20220098613A1 (en) | 2018-09-12 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
EP3852813A4 (en) | 2018-09-18 | 2022-06-22 | VNV Newco Inc. | ARC-BASED CAPSIDS AND THEIR USES |
WO2020072248A1 (en) | 2018-10-01 | 2020-04-09 | North Carolina State University | Recombinant type i crispr-cas system |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020097360A1 (en) * | 2018-11-07 | 2020-05-14 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for genome-wide analysis and use of genome cutting and repair |
US11384344B2 (en) | 2018-12-17 | 2022-07-12 | The Broad Institute, Inc. | CRISPR-associated transposase systems and methods of use thereof |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
TW202039845A (zh) * | 2018-12-20 | 2020-11-01 | 北京大學 | 使用加標籤的嚮導rna構建體進行高效基因篩選的組合物和方法 |
JP7144618B2 (ja) * | 2018-12-20 | 2022-09-29 | 北京大学 | バーコード付きガイドrna構築体を使用する効率的な遺伝子スクリーニングのための組成物及び方法 |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020191239A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
WO2020206036A1 (en) | 2019-04-01 | 2020-10-08 | The Broad Institute, Inc. | Novel nucleic acid modifier |
CN111812066B (zh) * | 2019-04-10 | 2023-04-28 | 华东理工大学 | 基于CRISPR/Cas12a系统的生物传感器、试剂盒及其在小分子检测中的用途 |
UY38693A (es) | 2019-05-13 | 2020-12-31 | Kws Saat Se & Co Kgaa | Tolerancia a la sequía en maíz |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
AR118995A1 (es) | 2019-05-25 | 2021-11-17 | Kws Saat Se & Co Kgaa | Mejorador de la inducción de haploides |
US20220243178A1 (en) | 2019-05-31 | 2022-08-04 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
MX2021015433A (es) | 2019-07-02 | 2022-06-08 | Hutchinson Fred Cancer Res | Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas. |
CN112168808B (zh) * | 2019-07-02 | 2023-01-24 | 深圳市第二人民医院 | 一种基于crispr的细胞核靶向药物递送系统 |
CN114174510A (zh) * | 2019-08-01 | 2022-03-11 | 安斯泰来制药株式会社 | 添加了功能性碱基序列的靶标编辑指导rna |
EP3772542A1 (en) | 2019-08-07 | 2021-02-10 | KWS SAAT SE & Co. KGaA | Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2 |
US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
CN115175996A (zh) | 2019-09-20 | 2022-10-11 | 博德研究所 | 新颖vi型crispr酶和系统 |
EP4045522A1 (en) | 2019-10-17 | 2022-08-24 | KWS SAAT SE & Co. KGaA | Enhanced disease resistance of crops by downregulation of repressor genes |
EP3872190A1 (en) | 2020-02-26 | 2021-09-01 | Antibodies-Online GmbH | A method of using cut&run or cut&tag to validate crispr-cas targeting |
DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
AR122206A1 (es) | 2020-05-29 | 2022-08-24 | Kws Saat Se & Co Kgaa | Inducción de haploides en plantas |
CN111979266A (zh) * | 2020-08-28 | 2020-11-24 | 江苏集萃药康生物科技有限公司 | 一种pcsk9人源化小鼠模型的构建方法及其应用 |
EP4001429A1 (en) | 2020-11-16 | 2022-05-25 | Antibodies-Online GmbH | Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq) |
CN114606196A (zh) * | 2020-12-04 | 2022-06-10 | 南京大学 | 一种进行siRNA表达和体内递送的细胞疗法 |
CN112899306B (zh) * | 2020-12-21 | 2023-06-30 | 南京启真基因工程有限公司 | Crispr系统及其在构建gabrg2基因突变的克隆猪核供体细胞中的应用 |
WO2023006933A1 (en) | 2021-07-30 | 2023-02-02 | KWS SAAT SE & Co. KGaA | Plants with improved digestibility and marker haplotypes |
CA3230927A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023093862A1 (en) | 2021-11-26 | 2023-06-01 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2024020352A1 (en) * | 2022-07-18 | 2024-01-25 | Vertex Pharmaceuticals Incorporated | Tandem guide rnas (tg-rnas) and their use in genome editing |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024042199A1 (en) | 2022-08-26 | 2024-02-29 | KWS SAAT SE & Co. KGaA | Use of paired genes in hybrid breeding |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US7150982B2 (en) | 1991-09-09 | 2006-12-19 | Third Wave Technologies, Inc. | RNA detection assays |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US7745416B2 (en) | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
AU698739B2 (en) | 1995-06-06 | 1998-11-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
US5622856A (en) | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
US6251677B1 (en) | 1997-08-25 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
NZ504214A (en) | 1997-10-24 | 2003-06-30 | Invitrogen Corp | Recombination cloning using nucleic acids having recombination sites |
US6750059B1 (en) | 1998-07-16 | 2004-06-15 | Whatman, Inc. | Archiving of vectors |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
US7033744B2 (en) | 2001-03-16 | 2006-04-25 | Naoya Kobayashi | Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof |
CA2446462C (en) | 2001-04-05 | 2015-12-22 | The Johns Hopkins University | Chimeric vaccines |
CA2453183C (en) | 2001-07-12 | 2016-05-10 | University Of Massachusetts | In vivo production of small interfering rnas that mediate gene silencing |
EP1572885A2 (en) | 2001-08-08 | 2005-09-14 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
US7776321B2 (en) | 2001-09-26 | 2010-08-17 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
WO2003087993A2 (en) | 2002-04-09 | 2003-10-23 | Beattie Kenneth L | Oligonucleotide probes for genosensor chips |
WO2003104414A2 (en) | 2002-06-11 | 2003-12-18 | The Scripps Research Institute | Artificial transcription factors |
CA2499188A1 (en) | 2002-09-27 | 2004-04-08 | Cold Spring Harbor Laboratory | Cell-based rna interference and related methods and compositions |
US9534224B2 (en) | 2002-11-15 | 2017-01-03 | Trustees Of Boston University | Cis/trans riboregulators |
US20060178297A1 (en) | 2003-01-28 | 2006-08-10 | Troy Carol M | Systems and methods for silencing expression of a gene in a cell and uses thereof |
MXPA05014215A (es) | 2003-07-03 | 2006-03-13 | Univ California | Mapeo de genoma de elementos funcionales de adn y proteinas celulares. |
EP2927318B1 (en) | 2003-08-08 | 2020-05-20 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2005035718A2 (en) | 2003-10-03 | 2005-04-21 | Welgen, Inc. | Biderectional promoters for small rna expression |
FR2862659B1 (fr) | 2003-11-21 | 2006-02-10 | Pasteur Institut | Genome de legionella pneumophila souche paris- applications diagnostiques et epidemiologiques |
WO2005070948A1 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing |
WO2005074511A2 (en) | 2004-01-27 | 2005-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for homozygous gene inactivation using collections of pre-defined nucleotide sequences complementary to chromosomal transcripts |
US20050220796A1 (en) | 2004-03-31 | 2005-10-06 | Dynan William S | Compositions and methods for modulating DNA repair |
FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
WO2006020071A2 (en) | 2004-07-16 | 2006-02-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines against aids comprising cmv/r-nucleic acid constructs |
EP1874794A4 (en) | 2005-04-28 | 2009-07-29 | Benitec Ltd | MULTIPLE RNAI EXPRESSION CASSETTES FOR THE SIMULTANEOUS DELIVERY OF RNAI AGENTS ASSOCIATED WITH HETEROZYGOT EXPRESSION PATTERNS |
US7892224B2 (en) | 2005-06-01 | 2011-02-22 | Brainlab Ag | Inverse catheter planning |
CA2615532C (en) | 2005-07-26 | 2016-06-28 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
EP2325332B1 (en) | 2005-08-26 | 2012-10-31 | DuPont Nutrition Biosciences ApS | Use of CRISPR associated genes (CAS) |
WO2007091269A2 (en) * | 2006-02-08 | 2007-08-16 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
EP1994182B1 (en) | 2006-03-15 | 2019-05-29 | Siemens Healthcare Diagnostics Inc. | Degenerate nucleobase analogs |
NZ572666A (en) | 2006-05-11 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene |
WO2008054544A2 (en) | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
WO2008093152A1 (en) | 2007-02-01 | 2008-08-07 | Cellectis | Obligate heterodimer meganucleases and uses thereof |
NZ592231A (en) | 2007-03-02 | 2012-07-27 | Danisco | Methods to generate bacteriophage resistant bacterial strains and produce bacteriophage CRISPR loci phage mutants |
PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス,インコーポレイテッド | 心不全の治療用のrna干渉 |
WO2009105690A2 (en) | 2008-02-21 | 2009-08-27 | Targeted Genetics Corporation | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
CN104910025B (zh) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | 氨基醇类脂质和其用途 |
EP2352369B1 (en) | 2008-12-04 | 2017-04-26 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
US20110016540A1 (en) | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of genes associated with trinucleotide repeat expansion disorders in animals |
AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
WO2010075424A2 (en) | 2008-12-22 | 2010-07-01 | The Regents Of University Of California | Compositions and methods for downregulating prokaryotic genes |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
WO2011036510A1 (en) | 2009-09-24 | 2011-03-31 | Cellectis | Meganuclease variants cleaving the genome of the herpes simplex virus and uses thereof |
US20120149115A1 (en) * | 2009-06-11 | 2012-06-14 | Snu R&Db Foundation | Targeted genomic rearrangements using site-specific nucleases |
KR20120097483A (ko) | 2009-07-24 | 2012-09-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 게놈 편집을 위한 방법 |
EP2727600B1 (en) | 2009-07-28 | 2019-03-27 | Sangamo Therapeutics, Inc. | Zinc finger fusion proteins for repressing a huntington gene |
US8927807B2 (en) | 2009-09-03 | 2015-01-06 | The Regents Of The University Of California | Nitrate-responsive promoter |
US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
EP2504439B1 (en) | 2009-11-27 | 2016-03-02 | BASF Plant Science Company GmbH | Optimized endonucleases and uses thereof |
CA2784547A1 (en) | 2009-12-23 | 2011-06-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Influenza targets |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
KR101867359B1 (ko) | 2010-05-10 | 2018-07-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 엔도리보뉴클레아제 조성물들 및 이들의 사용 방법들 |
WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
EP3489359A1 (en) * | 2010-07-23 | 2019-05-29 | Sigma Aldrich Co. LLC | Genome editing using targeting endonucleases and single-stranded nucleic acids |
US9081737B2 (en) | 2010-08-02 | 2015-07-14 | Integrated Dna Technologies, Inc. | Methods for predicting stability and melting temperatures of nucleic acid duplexes |
WO2012031205A2 (en) | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
RU2608643C2 (ru) | 2010-10-12 | 2017-01-23 | Дзе Чилдрен`З Хоспитал Оф Филадельфия | Способы и композиции для лечения гемофилии в |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
WO2012149470A1 (en) | 2011-04-27 | 2012-11-01 | Amyris, Inc. | Methods for genomic modification |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US9394545B2 (en) | 2011-09-21 | 2016-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
EP2764102A4 (en) | 2011-10-06 | 2015-06-10 | Sangamo Biosciences Inc | METHOD AND COMPOSITIONS FOR REGULATING HIV INFECTIONS |
EP2591770B1 (en) | 2011-11-14 | 2016-03-16 | Silenseed Ltd | Compositions for siRNA delivery and methods of manufacturing and using same |
JP6259766B2 (ja) | 2011-11-18 | 2018-01-10 | ユニヴェルシテ ラヴァルUniversite Laval | フラタキシンレベルを増加させる方法および生成物ならびにその使用 |
WO2013078400A1 (en) | 2011-11-22 | 2013-05-30 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
US8841260B2 (en) | 2012-02-29 | 2014-09-23 | Sangamo Biosciences, Inc. | Methods and compositions for treating Huntington's Disease |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
AU2013204327B2 (en) | 2012-04-20 | 2016-09-01 | Aviagen | Cell transfection method |
RS64622B1 (sr) | 2012-05-25 | 2023-10-31 | Univ California | Metode i sastavi za modifikaciju ciljane dnk upravljenu pomoću rnk i za modulaciju transkripcije upravljanu rnk |
BR112014029697A2 (pt) | 2012-06-01 | 2017-08-08 | Baruch S Blumberg Inst | método para modular a transcrição de cccdna de hepatite b em um indivíduo, método para modular dna circular covalentemente fechado de vírus da hepatite b e composto |
DK2906684T3 (da) | 2012-10-10 | 2020-09-28 | Sangamo Therapeutics Inc | T-celle-modificerende forbindelser og anvendelser deraf |
JP6517143B2 (ja) | 2012-10-23 | 2019-05-22 | ツールゲン インコーポレイテッド | 標的dnaに特異的なガイドrnaおよびcasタンパク質コード核酸またはcasタンパク質を含む、標的dnaを切断するための組成物、ならびにその使用 |
KR102006880B1 (ko) | 2012-12-06 | 2019-08-02 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
PT2896697E (pt) | 2012-12-12 | 2015-12-31 | Massachusetts Inst Technology | Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências |
EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
WO2014093718A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
PT2898075E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências |
DK2931898T3 (da) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | Konstruktion og optimering af systemer, fremgangsmåder og sammensætninger til sekvensmanipulation med funktionelle domæner |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
EP4286402A3 (en) | 2012-12-12 | 2024-02-14 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
SG11201504621RA (en) | 2012-12-17 | 2015-07-30 | Harvard College | Rna-guided human genome engineering |
CA2898184A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US10660943B2 (en) | 2013-02-07 | 2020-05-26 | The Rockefeller University | Sequence specific antimicrobials |
US9163837B2 (en) | 2013-02-27 | 2015-10-20 | Siemens Aktiengesellschaft | Flow conditioner in a combustor of a gas turbine engine |
ES2901396T3 (es) | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
US10119133B2 (en) | 2013-03-15 | 2018-11-06 | The General Hospital Corporation | Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing |
KR102109069B1 (ko) | 2013-03-27 | 2020-05-12 | 윌코아게 | 디바이스들을 인라인 검사 및/또는 테스트하는 방법 및 그와 같은 방법을 수행하는 장치 |
JP6576904B2 (ja) | 2013-04-04 | 2019-09-18 | トラスティーズ・オブ・ダートマス・カレッジ | HIV−1プロウイルスDNAのinvivo切除のための組成物及び方法 |
EP2997146A4 (en) | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
DK3004349T3 (da) | 2013-05-29 | 2018-06-06 | Cellectis Sa | En fremgangsmåde til fremstilling af præcis DNA-spaltning under anvendelse af CAS9-nickase aktivitet |
WO2014197568A2 (en) | 2013-06-04 | 2014-12-11 | President And Fellows Of Harvard College | Rna-guideded transcriptional regulation |
US9267135B2 (en) | 2013-06-04 | 2016-02-23 | President And Fellows Of Harvard College | RNA-guided transcriptional regulation |
AU2014274840B2 (en) | 2013-06-05 | 2020-03-12 | Duke University | RNA-guided gene editing and gene regulation |
EP3011032B1 (en) | 2013-06-17 | 2019-10-16 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
AU2014281027A1 (en) | 2013-06-17 | 2016-01-28 | Massachusetts Institute Of Technology | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
RU2716420C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
KR20160044457A (ko) | 2013-06-17 | 2016-04-25 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 탠덤 안내 시스템, 방법 및 조성물의 전달, 조작 및 최적화 |
SG10201710487VA (en) | 2013-06-17 | 2018-01-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components |
AU2014287009B2 (en) | 2013-07-11 | 2020-10-29 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
CN103388006B (zh) * | 2013-07-26 | 2015-10-28 | 华东师范大学 | 一种基因定点突变的构建方法 |
BR112016004091A2 (pt) | 2013-08-29 | 2017-10-17 | Univ Temple | métodos e composições para tratamento guiado por rna de infecção por hiv |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
KR102523466B1 (ko) | 2013-11-07 | 2023-04-20 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
EP3760719A1 (en) | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
AU2014362248A1 (en) | 2013-12-12 | 2016-06-16 | Massachusetts Institute Of Technology | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
AU2014361834B2 (en) | 2013-12-12 | 2020-10-22 | Massachusetts Institute Of Technology | CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes |
CN103668472B (zh) | 2013-12-31 | 2014-12-24 | 北京大学 | 利用CRISPR/Cas9系统构建真核基因敲除文库的方法 |
WO2015113063A1 (en) | 2014-01-27 | 2015-07-30 | Georgia Tech Research Corporation | Methods and systems for identifying crispr/cas off-target sites |
JP6323228B2 (ja) | 2014-07-18 | 2018-05-16 | 富士電機株式会社 | 電力変換装置 |
US9932566B2 (en) | 2014-08-07 | 2018-04-03 | Agilent Technologies, Inc. | CIS-blocked guide RNA |
EP3180426B1 (en) | 2014-08-17 | 2019-12-25 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
KR102575342B1 (ko) | 2015-06-18 | 2023-09-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적외 효과를 감소시키는 crispr 효소 돌연변이 |
US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
JP6186470B2 (ja) | 2016-04-20 | 2017-08-23 | パイオニア株式会社 | 音響装置、音量制御方法、音量制御プログラム及び記録媒体 |
-
2014
- 2014-06-10 KR KR1020167001305A patent/KR20160044457A/ko not_active Application Discontinuation
- 2014-06-10 WO PCT/US2014/041800 patent/WO2014204724A1/en active Application Filing
- 2014-06-10 EP EP19212058.2A patent/EP3674411A1/en active Pending
- 2014-06-10 AU AU2014281026A patent/AU2014281026B2/en active Active
- 2014-06-10 DK DK14734708.2T patent/DK3011029T3/da active
- 2014-06-10 EP EP14734708.2A patent/EP3011029B1/en active Active
- 2014-06-10 CN CN201480045695.3A patent/CN106062197A/zh active Pending
- 2014-06-10 ES ES14734708T patent/ES2777217T3/es active Active
- 2014-06-10 JP JP2016521449A patent/JP6625971B2/ja active Active
- 2014-06-10 CA CA2915834A patent/CA2915834A1/en not_active Abandoned
-
2015
- 2015-12-17 US US14/972,927 patent/US11008588B2/en active Active
-
2016
- 2016-10-11 HK HK16111709.1A patent/HK1223646A1/zh unknown
-
2019
- 2019-11-28 JP JP2019215361A patent/JP2020054354A/ja active Pending
-
2021
- 2021-05-17 US US17/321,872 patent/US20210292794A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2777217T3 (es) | 2020-08-04 |
AU2014281026A9 (en) | 2016-06-16 |
JP2016521993A (ja) | 2016-07-28 |
KR20160044457A (ko) | 2016-04-25 |
US20160186213A1 (en) | 2016-06-30 |
EP3674411A1 (en) | 2020-07-01 |
CN106062197A (zh) | 2016-10-26 |
WO2014204724A9 (en) | 2016-03-24 |
US20210292794A1 (en) | 2021-09-23 |
EP3011029A1 (en) | 2016-04-27 |
JP6625971B2 (ja) | 2019-12-25 |
US11008588B2 (en) | 2021-05-18 |
JP2020054354A (ja) | 2020-04-09 |
HK1223646A1 (zh) | 2017-08-04 |
AU2014281026A1 (en) | 2016-01-28 |
WO2014204724A1 (en) | 2014-12-24 |
CA2915834A1 (en) | 2014-12-24 |
EP3011029B1 (en) | 2019-12-11 |
WO2014204724A8 (en) | 2015-12-23 |
AU2014281026B2 (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3011029T3 (da) | Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering | |
DK3327127T3 (da) | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til sekvensmanipulation og terapeutiske anvendelser | |
DK3656557T3 (da) | System og arbejdsstation til design, fabrikation og fremstilling af biomaterielle konstruktioner | |
DK3064585T3 (da) | Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation | |
DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
DK3139986T3 (da) | System til administration af terapeutisk gas | |
DK3291679T3 (da) | Ændring af mikrobielle populationer og modificering af mikrobiota | |
DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
DK2970872T3 (da) | Mikroorganismer og fremgangsmåder til fremstilling af sialylerede og N-acetylglucosamin-holdige oligosaccharider | |
DK2996556T3 (da) | System til billedstyret procedure | |
DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
DK2943192T3 (da) | Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin | |
DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
DK2954051T3 (da) | Modificeret kapsid til genoverførsel til behandling af nethinden | |
DK3071704T3 (da) | System og fremgangsmåde til sortering af sperm | |
DK2958900T3 (da) | 2-aminopyrimidinderivater til behandling af virusinfektioner | |
DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
DK3019503T3 (da) | Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner | |
DK3019499T3 (da) | Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner | |
DK3172233T3 (da) | Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer | |
DK3300610T3 (da) | Fremgangsmåde til fraktionering af opløselige ærter | |
DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
DK3300015T3 (da) | System til fremstilling af individuelle formuleringer til individer | |
DK3025586T3 (da) | Sammensætning til bekæmpelse af plantesygdomme og anvendelse deraf |